Literature DB >> 29705261

Vibration-Controlled Transient Elastography to Assess Fibrosis and Steatosis in Patients With Nonalcoholic Fatty Liver Disease.

Mohammad S Siddiqui1, Raj Vuppalanchi1, Mark L Van Natta2, Erin Hallinan2, Kris V Kowdley3, Manal Abdelmalek4, Brent A Neuschwander-Tetri5, Rohit Loomba6, Srinivasan Dasarathy7, Danielle Brandman8, Edward Doo9, James A Tonascia2, David E Kleiner10, Naga Chalasani11, Arun J Sanyal1.   

Abstract

BACKGROUND & AIMS: Vibration-controlled transient elastography (VCTE), which measures liver stiffness, has become an important tool for evaluating patients with nonalcoholic fatty liver disease (NAFLD). We aimed to determine the diagnostic accuracy of VCTE in detection of NAFLD in a multicenter cohort of patients.
METHODS: We performed a prospective study of 393 adults with NAFLD who underwent VCTE within 1 year of liver histology analysis (median time, 49 d; interquartile range, 25-78 d), from July 1, 2014, through July 31, 2017. Liver stiffness measurement (LSM) cut-off values for pairwise fibrosis stage and controlled attenuation parameter cut-off values for pairwise steatosis grade were determined using cross-validated area under the receiver operating characteristics curve (AUROC) analyses. Diagnostic statistics were computed at a sensitivity fixed at 90% and a specificity fixed at 90%.
RESULTS: LSM identified patients with advanced fibrosis with an AUROC of 0.83 (95% CI, 0.79- 0.87) and patients with cirrhosis with an AUROC of 0.93 (95% CI, 0.90-0.97). At a fixed sensitivity, a cut-off LSM of 6.5 kPa excluded advanced fibrosis with a negative predictive value of 0.91, and a cut-off LSM of 12.1 kPa excluded cirrhosis with a negative predictive value of 0.99. At a fixed specificity, LSM identified patients with advanced fibrosis with a positive predictive value of 0.71 and patients with cirrhosis with a positive predictive value of 0.41. Controlled attenuation parameter analysis detected steatosis with an AUROC of 0.76 (95% CI, 0.64-0.87). In contrast, the VCTE was less accurate in distinguishing lower fibrosis stages, higher steatosis grades, or the presence of NASH.
CONCLUSIONS: In a prospective study of adults with NAFLD, we found VCTE to accurately distinguish advanced vs earlier stages of fibrosis, using liver histology as the reference standard.
Copyright © 2019 AGA Institute. Published by Elsevier Inc. All rights reserved.

Entities:  

Keywords:  Controlled Attenuation Parameter; Fibroscan; Fibrosis; NAFLD; Steatosis; VCTE; Vibration Controlled Transient Elastography

Mesh:

Year:  2018        PMID: 29705261      PMCID: PMC6203668          DOI: 10.1016/j.cgh.2018.04.043

Source DB:  PubMed          Journal:  Clin Gastroenterol Hepatol        ISSN: 1542-3565            Impact factor:   11.382


  22 in total

1.  Comparative diagnostic accuracy of magnetic resonance elastography vs. eight clinical prediction rules for non-invasive diagnosis of advanced fibrosis in biopsy-proven non-alcoholic fatty liver disease: a prospective study.

Authors:  J Cui; B Ang; W Haufe; C Hernandez; E C Verna; C B Sirlin; R Loomba
Journal:  Aliment Pharmacol Ther       Date:  2015-04-15       Impact factor: 8.171

2.  Liver biopsy.

Authors:  Don C Rockey; Stephen H Caldwell; Zachary D Goodman; Rendon C Nelson; Alastair D Smith
Journal:  Hepatology       Date:  2009-03       Impact factor: 17.425

3.  Changes in the prevalence of the most common causes of chronic liver diseases in the United States from 1988 to 2008.

Authors:  Zobair M Younossi; Maria Stepanova; Mariam Afendy; Yun Fang; Youssef Younossi; Hesham Mir; Manirath Srishord
Journal:  Clin Gastroenterol Hepatol       Date:  2011-03-25       Impact factor: 11.382

4.  Changes in liver stiffness measurement during antiviral therapy in patients with chronic hepatitis B.

Authors:  Sun Gyo Lim; Sung Won Cho; Yoon Chul Lee; Su Jin Jeon; Myoung Hee Lee; Young Ju Cho; Soon Sun Kim; Young Bae Kim; Jae Yeon Seok; Jae Youn Cheong; Jin Hong Kim
Journal:  Hepatogastroenterology       Date:  2011 Mar-Apr

5.  Design and validation of a histological scoring system for nonalcoholic fatty liver disease.

Authors:  David E Kleiner; Elizabeth M Brunt; Mark Van Natta; Cynthia Behling; Melissa J Contos; Oscar W Cummings; Linda D Ferrell; Yao-Chang Liu; Michael S Torbenson; Aynur Unalp-Arida; Matthew Yeh; Arthur J McCullough; Arun J Sanyal
Journal:  Hepatology       Date:  2005-06       Impact factor: 17.425

6.  Magnetic Resonance Elastography vs Transient Elastography in Detection of Fibrosis and Noninvasive Measurement of Steatosis in Patients With Biopsy-Proven Nonalcoholic Fatty Liver Disease.

Authors:  Charlie C Park; Phirum Nguyen; Carolyn Hernandez; Ricki Bettencourt; Kimberly Ramirez; Lynda Fortney; Jonathan Hooker; Ethan Sy; Michael T Savides; Mosab H Alquiraish; Mark A Valasek; Emily Rizo; Lisa Richards; David Brenner; Claude B Sirlin; Rohit Loomba
Journal:  Gastroenterology       Date:  2016-10-27       Impact factor: 22.682

7.  Liver stiffness measurement using XL probe in patients with nonalcoholic fatty liver disease.

Authors:  Vincent Wai-Sun Wong; Julien Vergniol; Grace Lai-Hung Wong; Juliette Foucher; Anthony Wing-Hung Chan; Faiza Chermak; Paul Cheung-Lung Choi; Wassil Merrouche; Shirley Ho-Ting Chu; Sophie Pesque; Henry Lik-Yuen Chan; Victor de Lédinghen
Journal:  Am J Gastroenterol       Date:  2012-10-02       Impact factor: 10.864

8.  NASH and cryptogenic cirrhosis: a histological analysis.

Authors:  Stephen H Caldwell; Vanessa D Lee; David E Kleiner; Abdullah M S Al-Osaimi; Curtis K Argo; Patrick G Northup; Carl L Berg
Journal:  Ann Hepatol       Date:  2009 Oct-Dec       Impact factor: 2.400

9.  The Performance of Vibration Controlled Transient Elastography in a US Cohort of Patients With Nonalcoholic Fatty Liver Disease.

Authors:  Elliot B Tapper; Tracy Challies; Imad Nasser; Nezam H Afdhal; Michelle Lai
Journal:  Am J Gastroenterol       Date:  2016-03-15       Impact factor: 10.864

10.  Discordance between liver biopsy and Fibroscan® in assessing liver fibrosis in chronic hepatitis b: risk factors and influence of necroinflammation.

Authors:  Seung Up Kim; Ja Kyung Kim; Young Nyun Park; Kwang-Hyub Han
Journal:  PLoS One       Date:  2012-02-23       Impact factor: 3.240

View more
  79 in total

1.  Usefulness of Controlled Attenuation Parameter in Detecting and Monitoring Hepatic Steatosis with MRI-PDFF as Reference.

Authors:  Jing-Houng Wang; Hsin-You Ou; Yi-Hao Yen; Chien-Hung Chen; Sheng-Nan Lu
Journal:  Dig Dis Sci       Date:  2019-10-15       Impact factor: 3.199

Review 2.  Advances in non-invasive biomarkers for the diagnosis and monitoring of non-alcoholic fatty liver disease.

Authors:  Michelle T Long; Sanil Gandhi; Rohit Loomba
Journal:  Metabolism       Date:  2020-05-05       Impact factor: 8.694

Review 3.  Implications of Nonalcoholic Steatohepatitis as the Cause of End-Stage Liver Disease Before and After Liver Transplant.

Authors:  Anchalia Chandrakumaran; Mohammad Shadab Siddiqui
Journal:  Gastroenterol Clin North Am       Date:  2020-03       Impact factor: 3.806

4.  Histologic Findings of Advanced Fibrosis and Cirrhosis in Patients With Nonalcoholic Fatty Liver Disease Who Have Normal Aminotransferase Levels.

Authors:  Samer Gawrieh; Laura A Wilson; Oscar W Cummings; Jeanne M Clark; Rohit Loomba; Bilal Hameed; Manal F Abdelmalek; Srinivasan Dasarathy; Brent A Neuschwander-Tetri; Kris Kowdley; David Kleiner; Edward Doo; James Tonascia; Arun Sanyal; Naga Chalasani
Journal:  Am J Gastroenterol       Date:  2019-10       Impact factor: 10.864

5.  Prevalence and Severity of Nonalcoholic Fatty Liver Disease Among Caregivers of Patients With Nonalcoholic Fatty Liver Disease Cirrhosis.

Authors:  Mohammad Shadab Siddiqui; Salvatore Carbone; Robert Vincent; Samarth Patel; Carolyn Driscoll; Francesco S Celi; Hayley Billingsley; Brando Rotelli; Binu John; Nicola Potere; Michele Viscusi; Veronica Adiletta; Arun J Sanyal; Velimir A Luketic; Trevor Reichman; Chandra S Bhati
Journal:  Clin Gastroenterol Hepatol       Date:  2018-11-15       Impact factor: 11.382

Review 6.  The Role of Noninvasive Tests for Differentiating NASH From NAFL and Diagnosing Advanced Fibrosis Among Patients With NAFLD.

Authors:  Maya Balakrishnan; Rohit Loomba
Journal:  J Clin Gastroenterol       Date:  2020-02       Impact factor: 3.062

7.  Evaluation and comparison of six noninvasive tests for prediction of significant or advanced fibrosis in nonalcoholic fatty liver disease.

Authors:  Katharina Staufer; Emina Halilbasic; Walter Spindelboeck; Magdalena Eilenberg; Gerhard Prager; Vanessa Stadlbauer; Andreas Posch; Petra Munda; Rodrig Marculescu; Barbara Obermayer-Pietsch; Judith Stift; Carolin Lackner; Michael Trauner; Rudolf E Stauber
Journal:  United European Gastroenterol J       Date:  2019-07-12       Impact factor: 4.623

8.  Diagnostic Performance of Vibration-Controlled Transient Elastography in Liver Transplant Recipients.

Authors:  Mohammad Shadab Siddiqui; Michael O Idowu; Katharine Stromberg; Adam Sima; Emily Lee; Samarth Patel; Sophia Ghaus; Carolyn Driscoll; Richard K Sterling; Binu John; Chandra S Bhati
Journal:  Clin Gastroenterol Hepatol       Date:  2020-04-06       Impact factor: 11.382

9.  Noninvasive stratification of nonalcoholic fatty liver disease by whole transcriptome cell-free mRNA characterization.

Authors:  Naga Chalasani; Shusuke Toden; John J Sninsky; Richard P Rava; Jerome V Braun; Samer Gawrieh; Jiali Zhuang; Michael Nerenberg; Stephen R Quake; Tara Maddala
Journal:  Am J Physiol Gastrointest Liver Physiol       Date:  2021-01-27       Impact factor: 4.052

10.  Prevalence of Nonalcoholic Fatty Liver Disease and Hepatic Fibrosis Among US Adults with Prediabetes and Diabetes, NHANES 2017-2018.

Authors:  Donghee Kim; George Cholankeril; Rohit Loomba; Aijaz Ahmed
Journal:  J Gen Intern Med       Date:  2021-03-05       Impact factor: 5.128

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.